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With the aim of investigating whether interleukin 28B gene (IL28B) rs1297860 polymorphism is associated with different hepatitis
C (HCV) infection statuses, we compared IL28B allelic distribution in an Italian case series of 1050 patients with chronic infection
and different outcomes, 47 individuals who spontaneously cleared HCV, and 178 blood donors. Furthermore, we compared IL28B
variants among 3882 Caucasian patients with chronic infection, 397 with spontaneous clearance, and 1366 blood donors reported
in PubMed. Overall data confirmed a relation between IL28B C allele andHCV spontaneous clearance. Furthermore, we found that
IL28B T allele had a weak relation with chronic HCV progression to hepatocellular carcinoma. Study findings are in accordance
with the hepatocellular carcinogenic model where IL28B TT genotype, by promoting a persistent chronic hepatitis which leads to
both hepatocyte injury and chronic inflammation, could facilitateHCCdevelopment. Conversely, patients with lymphoproliferative
disorders had not any significantly different IL28B rs1297860 allelic distribution than those with chronic HCV, but, like all chronic
HCV-related diseases, they showed a lower CC frequency than patients who spontaneously cleared HCV. Study results confirmed
the model of persistent HCV infection as a risk factor for the pathogenesis of both liver and lymphoproliferative disorders.
1. Introduction
Hepatitis C virus (HCV), a positive-strand RNA virus widely
diffused (about 2-3%) around the world, is a major causative
agent of chronic liver diseases, including hepatitis, cirrhosis,
and hepatocellular carcinoma (HCC) [1, 2]. HCV infec-
tion is also associated with lymphoproliferative disorders,
represented by mixed type II cryoglobulinemia (MC) and
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Table 1: Caucasian patients included in IL28B rs12979860 analysis with different HCV-related outcomes reported in the literature (PubMed)
between 2009 and 2013.
Article Blood donors(HCV neg.)
Spontaneous
clearance of
HCV
Chronic
HCV
Mild/moderate
fibrosis Cirrhosis
Hepatocellular
carcinoma
Mixed
cryoglobulinemia
S.
Mangia et al. (2013)
[13] 178 47 122
Sharafi et al. (2012)
[17] 142 921
Piluso et al. (2013)
[15] 231 250
Falleti et al. (2011)
[11] 428 429 200
Knapp et al. (2011)
[12] 74 89 234
Fabris et al. (2011)
[32] 344 235 199 35
Sarrazin et al.
(2011) [16] 200 645
Thomas et al.
(2009) [18] 261 381
Total 1366 397 2534 664 399 35 250
B-cell non-Hodgkin’s lymphomas (NHLs) [3–6]. The reason
for such different outcome of HCV infection among patients
is still largely unknown.
Traditional therapy for treatment of chronic HCV invol-
ves pegylated type I IFN (PEG-IFN) in combination with
ribavirin. This treatment eradicates HCV infection in only
40%–50% of patients infected with genotypes 1 or 4 and 75%–
90% of those infected with genotypes 2 or 3 [7, 8]. However,
adverse effects due to this treatment regimen frequently lead
to poor tolerance.
Recent studies have reported that human genetic vari-
ants, in particular rs1297860 single nucleotide polymorphism
(SNP), within or near the interleukin 28B gene (IL28B) are
significantly associated with spontaneous HCV clearance as
well as different outcomes of treatment with IFN/ribavirin
therapy for chronic HCV infection [9–19]. The relation is
more evident for HCV genotype 1 infection. These observa-
tions suggest an important role of IL28B against HCV
infection and natural history of HCV outcomes.
IL28B is a member, along with IL-29 and IL-28A, of type
III interferons, also termed interferon-lambda (IFN-𝜆). They
have in common a strong antiviral function and induction of
interferon stimulated genes (ISGs) [20–24].
IFN-𝜆 signals through interferon-lambda receptor1
(IFNLR1) and interleukin-10 receptor2 (IL-10R2) result in
STAT phosphorylation, dimer formation, nuclear transloca-
tion, and then induction of ISG expression and upregulation
of major histocompatibility complex (MHC) class I [25].
IFN-𝜆 responsiveness is restricted to specific cell types
[26], partially because IFNLR1 tissue distribution is highly
restricted [27]. In contrast to the epithelial-like cells, fibrob-
lasts and endothelial cells were completely unresponsive to
IFN-𝜆. A good IFN-𝜆-induced response was shown in hepa-
tic cells, with an increased IFNLR1 expression after viral
infection [28]. Na¨ıve B and T cells, lymphocytes, and mono-
cytes, although express adequate amounts of IFNLR1 recep-
tor, respond poorly or not at all to IFN-𝜆 [28].This implies the
presence of specific mechanisms on the lymphoid tissues that
may inhibit the IFN-𝜆 response. This important functional
difference in tissue response to IFN-𝜆may provide a clinical
advantage from IFN-𝛼 as a treatment for chronic HCV
infection, as IFN-𝜆 is less likely to induce the leucopeniamost
often associatedwith IFN-𝛼 therapy andmay be used inHCV
patients who are resistant to IFN-𝛼. Moreover, it was found
that IFN-𝜆upregulates the production of cytokines by natural
killer (NK) and T cells [29] and reduces the proliferation of
regulatory T cells [30]; thus [31] it is supposed that lymphoid
cells respond to IFN-𝜆 by different signals than hepatic cells.
Due to the responsiveness of most cell types to IFN-𝜆 and
a limited toxicity, IFN-𝜆s are under study for clinical use not
only for anti-HCV therapy but also as anticancer and antiviral
drug [22].
The aim of this paper is to investigate whether a relation
between IL28B rs12979860 polymorphism and severity of
liver or lymphoproliferative diseases exists.
2. Material and Methods
2.1. Patients. We identified and reviewed papers published
from 2009 to 2013 analyzing Caucasian HCV-infected
patients for distribution of IL28B genetic variants, using the
online database pubMed. Selected studies included in the
analysis alongwith inclusion criteria were reported in Table 1.
We also analyzed the IL28B rs12979860 polymorphism in
a case series of 1050 HCV-infected patients, 47 individuals
who experienced spontaneous HCV clearance, and 178 blood
donors, from a cohort of HIV- and HBV-negative Italian
patients, referred to the following centers: MASVE Center,
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University of Florence, Florence; “Santa Maria degli Angeli”
General Hospital, Pordenone; National Cancer Institute
“Fondazione Pascale”, Naples; “Casa Sollievo della Sofferenza”
Hospital, San Giovanni Rotondo; “Azienda Ospedaliero-
Universitaria Consorziale Policlinico”, Bari; University Hos-
pital “Santa Maria della Misericordia”, Udine; Ospedale san
Gerardo-University of Milano-Bicocca, Monza; and National
Cancer Institute “Centro di Riferimento Oncologico”, CRO
Aviano National Cancer Institute. Our series of 1050 patients
with chronic HCV infection included group of patients with
absence of HCC or any sign/symptom of definiteMC orNHL
(CHC, 𝑛 = 536), patients with HCC (𝑛 = 95), patients with
a definite MC syndrome, according to previously described
criteria [33] (𝑛 = 352), and presence of a definite malignant
B-cell NHL (𝑛 = 67).
2.2. IL28B Genotyping. Genomic DNA was extracted from
peripheral blood which has been previously stored at −80∘C.
IL28B genotyping was performed using a specific
customized TaqMan SNP-genotyping Assay (rs12979860;
Applied Bosystem, Foster City, CA, USA) based on allele-
specific labeled probes on a Rotor Gene 6000 (Corbett
Research, Sidney, Australia). Amplicon sequencing was used
to validate the genotyping techniques.
2.3. Statistical Analysis. Frequencies (f) of IL28B rs12979860
C and T alleles and genotypes polymorphisms were deter-
mined individually by direct counting of the positive indi-
viduals for a specific genotype/allele polymorphism. The
observed and expected genotype frequencies among the
study groups were analyzed using the Hardy-Weinberg equi-
librium theory. Differences in f between groups of selected
patients were evaluated using Fisher’s exact test, Pearson’s chi-
square (𝜒2) test (withYates correction), orCochran-Armitage
𝑧
2 test for trend in frequencies as appropriate [34]. A two-
sided 𝑃 value <0.05 was considered as statistically significant.
3. Results
Reviewed data on IL28B variant distribution in different
HCV outcomes and limited to Caucasian subjects were
reported in Table 2. The genotype frequencies of the IL28B
rs12979860 polymorphism were found in Hardy-Weinberg
equilibrium in the blood donors group (Pearson’s 𝜒2 = 0.09;
df = 1; 𝑃 = 0.76).The IL28B rs12979860 C allele was related to
a significant increase in spontaneous clearance of the virus in
a dominant genetic model (CC versus CT + TT) employed to
compare HCV+ patients presenting spontaneous viral clear-
ance versus all other HCV+ subjects (Pearson’s 𝜒2 = 148.9;
𝑃 < 0.001). Data indicates that C allele had an important role
in the control of infection (Fisher’s test, 𝑃 < 0.001, Figure 1).
A significant negative linear trend was detected in the
order of the CC genotype frequencies of patients with an
increasing severity of liver diseases (from 40% in CHC to
17% in HCC, Figure 2; Cochran-Armitage’s 𝑧2 = 22.38, 𝑃 <
0.001), whereas a significant positive linear trend emerged
for TT genotype frequencies (from 12.0% in CHC to 22.8%
in HCC, Figure 2; Cochran-Armitage’s 𝑧2 = 8.42, 𝑃 = 0.004),
SC
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∗
n = 146
n = 648
n = 4830
n = 2934
All HCV+
∗Fisher’s exact test, P value < 0.01
Figure 1: IL28B rs12979860 C/T allele frequencies in patients with
spontaneous clearance (SC) of HCV infection versus all HCV+
patients. Caucasian individuals reported in literature (PubMed),
2009–2013.
CC CT TT
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en
t (
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0
10
20
30
40
50
60
70
∗
∗
P < 0.001
P = 0.004
Chronic HCV (n = 2534)
Fibrosis (n = 664)
Cirrhosis (n = 399)
Hepatocellular carcinoma (n = 35)
∗Cochran-Armitage trend test, P value < 0.01
Figure 2: IL28B rs12979860 genotype frequencies in patients
with HCV infection and different outcomes. Caucasian individuals
reported in literature (PubMed), 2009–2013.
suggesting an important role of CC allele in the control of
liver disease progression.
IL28B rs12979860 genotype frequencies found in our
case series were similar to those reported in the litera-
ture (Table 3). We found a slightly increasing trend in TT
genotype frequency in HCC (18.9%) with respect to that of
CHC (12.7%), but difference was not statistically significant
(Fisher’s test, 𝑃 = 0.106) (Figure 3). Given the modest
increase in HCC risk we found and the low number of
HCC cases included in this study (35 from the literature
BioMed Research International 5
and 95 in our case series), replication studied using larger
series of HCV+ HCC would need to confirm this finding.
However, carriage of TT genotype in blood donors (7.9%)
and in patients who spontaneously cleared the virus (2.1%)
was lower than that found in our HCC series (Fisher’s test,
𝑃 = 0.009 and 0.003, resp.). Moreover, similar to that found
in data from the literature, the frequency of CC genotype
was significantly higher among patients who spontaneously
cleared the virus compared to patients with CHC (Fisher’s
test, 𝑃 < 0.001) (Table 3 and Figure 3).
As regards the lymphoproliferative disorders associated
with HCV infection, the literature reported only one study
including patients with autoimmune MC syndrome [15] and
no study on NHL. Data obtained in our case series were
reported in Table 3.
In MC, IL28B CC genotype frequency was found similar
to that in blood donors (Figure 3); nonetheless, the carriage
of TT genotype in MC (15.1%) was weakly higher than that
among blood donors (7.9%, Fisher’s test, 𝑃 = 0.019) but
not significantly higher than that among CHC patients (12.9,
Fisher’s test, 𝑃 = 0.319). HCV positive patients with NHL
(11.9%) were very similar to CHC patients; in this case the
carriage of TT genotype was not significantly different.
4. Discussion
Several studies have indicated that IL28B rs12979860 poly-
morphism has a role in the response of HCV infection and
liver disease risk, but the knowledge of its overall effect on
the natural history of hepatitis viral infection remains partial
and limited to certain aspect in individual studies. In addi-
tion, data regarding the IL-28B rs12979860 risk towards a
HCV-related lymphoproliferative disorder (MC or NHL) is
even less known. Thus we conducted this study to evaluate
relations between IL-28B rs12979860 CT polymorphism and
natural history ofHCV infection by using the following inclu-
sion criteria: Caucasian individuals affected by HCV infec-
tion (excluding HBV or HIV co-infection) and different liver
or lymphoproliferative diseases related to HCV progression.
The analysis of aggregated data from the literature clearly
indicated that IL-28B rs12979860 allelic frequencies were
significantly different in patients who spontaneously cleared
HCV infection in comparison to patients with chronic HCV
infection. HCV+ patients who spontaneously cleared the
infection carried the CC genotype in 68.8% of cases, while
patients with chronic HCV infection and liver diseases car-
ried this genotype in a range from 39.6% to 17.1%.The IL-28B
C allele was inversely related to the risk of chronic and liver
diseases with respect to both blood donors and patients who
spontaneously eliminated the virus when the dominant gene-
tic model (CC versus CT + TT) was employed, in agreement
with previous idea that C allele is implicated in the control
of HCV infection. In addition, although resulting from a
limited number of cases analyzed (𝑛 = 35 from literature
[32], 𝑛 = 95 in our series), the carriage of TT genotype
and the presence of T allele were slightly prevalent in the
HCC group of patients. Due to the weak effect of IL28B T
allele found on the progression to HCC, replication of this
BD SC CHC HCC MC NHL
0
20
40
60
80
100
CC
CT
TT
∗
∗
∗
Pe
rc
en
t (
%
)
∗Fisher’s exact test, P value < 0.01
Figure 3: Genotype frequencies of IL28B rs12979860 C/T poly-
morphism in 178 blood donors (BD), 47 patients with spontaneous
clearance (SC) of HCV, 536 patients with chronic HCV (CHC), 95
patients with hepatocellular carcinoma (HCC), 352 patients with
mixed cryoglobulinemia syndrome (MC), and 67 patients with non-
Hodgkin’s lymphoma (NHL). Italian case series.
analysis in a large number of cases is required to confirm our
study finding. Anyhow, this finding is in accordance with
the HCC carcinogenic model where IL28B T allele carriage
was much more favorable to persistence of a chronic HCV
infection, which leads to both hepatocyte injury and chronic
inflammation in the liver, thus facilitating the HCC develop-
ment [35–37].
We presented for the first time a comparative analysis
of IL28B rs12979860 allelic distribution in patients with
chronic HCV infection and lymphoproliferative diseases
(Table 3 and Figure 3). No statistically significant differences
in IL28B rs12979860 allelic distribution emerged between
patients with lymphoproliferative disorders and other groups
of patients or blood donors. It should be noted, however,
that CC genotype was more frequent in patients with MC
(144/352, 40.9%) than in those with malignant tumors taken
together (HCC + NHL, 50/162, 30.9%, Fisher’s test 𝑃 =
0.031, data not shown in Tables). Moreover, TT genotype
was slightly more frequent, without reaching statistical sig-
nificance maybe because of low numbers, in patients with
an HCC (18.9%) than in those with a NHL (11.9%, Figure 3).
These findings could suggest that patients withMC syndrome
carrying IL28B rs12979860 CC, a genotype more favorable
to resolve the infection, should contrast both liver and
lymphoproliferativemalignant diseases and that patientswith
TT genotype could bemore predisposed to evolve towards an
HCC than a malignant lymphoma.
In conclusion, study results on overall data from the
literature and our case series confirmed that all chronicHCV-
related disorders presented a lower frequency of C allele as
compared to patients who spontaneously eliminated HCV,
thus supporting the model of persistent HCV infection as an
important risk factor for the pathogenesis of both liver and
lymphoproliferative disorders [3, 6]. Moreover, an additional
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risk factor related to TT homozygosis and liver disease
progression emerged from this study. Of note, since recently
a polymorphism (ss469415590) of a new interferon gene,
IFNL4, was found strongly associated with HCV clearance
and was in high linkage disequilibrium with IL28B [38]; fur-
ther studies are needed regarding IFNL4 polymorphism and
its possible involvement in the HCV-related malignancies.
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